Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures
Public ClinicalTrials.gov record NCT00520741. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400 mg/Day Monotherapy in Subjects With Partial-onset Seizures
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this historical-controlled trial is to demonstrate the efficacy and safety of conversion to Lacosamide monotherapy in subjects with Partial-onset Seizures who are withdrawn from 1 to 2 marketed antiepileptic drugs.
Study identification
- NCT ID
- NCT00520741
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 426 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 16 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2007 (Type not available)
- Primary completion
- Dec 2012 (Actual)
- Completion
- Dec 2012 (Actual)
- Last update posted
- Jul 19, 2018
2007 – 2012
United States locations
- U.S. sites
- 108
- U.S. states
- 38
- U.S. cities
- 96
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 48 | Alabaster | Alabama | — | — |
| 10 | Birmingham | Alabama | — | — |
| 18 | Huntsville | Alabama | — | — |
| 42 | Northport | Alabama | — | — |
| 14 | Phoenix | Arizona | — | — |
| 151 | Phoenix | Arizona | — | — |
| 9 | Phoenix | Arizona | — | — |
| 150 | Sun City | Arizona | — | — |
| 103 | Tucson | Arizona | — | — |
| 102 | Jonesboro | Arkansas | — | — |
| 7 | Little Rock | Arkansas | — | — |
| 86 | Little Rock | Arkansas | — | — |
| 120 | La Habra | California | — | — |
| 156 | Loma Linda | California | — | — |
| 59 | Los Angeles | California | — | — |
| 76 | Los Angeles | California | — | — |
| 45 | Newport Beach | California | — | — |
| 21 | Santa Monica | California | — | — |
| 107 | Torrance | California | — | — |
| 60 | Aurora | Colorado | — | — |
| 25 | Fairfield | Connecticut | — | — |
| 133 | Dover | Delaware | — | — |
| 37 | Washington D.C. | District of Columbia | — | — |
| 94 | Doral | Florida | — | — |
| 108 | Gainesville | Florida | — | — |
| 130 | Gulf Breeze | Florida | — | — |
| 55 | Maitland | Florida | — | — |
| 123 | Miami | Florida | — | — |
| 132 | Miami | Florida | — | — |
| 77 | Orlando | Florida | — | — |
| 49 | Panama City | Florida | — | — |
| 109 | Pinellas Park | Florida | — | — |
| 129 | Port Charlotte | Florida | — | — |
| 50 | Sarasota | Florida | — | — |
| 81 | Sarasota | Florida | — | — |
| 4 | Tallahassee | Florida | — | — |
| 163 | Tampa | Florida | — | — |
| 79 | Atlanta | Georgia | — | — |
| 72 | Canton | Georgia | — | — |
| 40 | Savannah | Georgia | — | — |
| 58 | Boise | Idaho | — | — |
| 131 | Hines | Illinois | — | — |
| 146 | Peoria | Illinois | — | — |
| 11 | Springfield | Illinois | — | — |
| 78 | Indianapolis | Indiana | — | — |
| 73 | Ames | Iowa | — | — |
| 124 | Manhattan | Kansas | — | — |
| 160 | Wichita | Kansas | — | — |
| 23 | Wichita | Kansas | — | — |
| 119 | Lexington | Kentucky | — | — |
| 164 | Lexington | Kentucky | — | — |
| 62 | Louisville | Kentucky | — | — |
| 29 | Scarborough | Maine | — | — |
| 20 | Baltimore | Maryland | — | — |
| 34 | Baltimore | Maryland | — | — |
| 19 | Bethesda | Maryland | — | — |
| 65 | Pikesville | Maryland | — | — |
| 137 | Waldorf | Maryland | — | — |
| 41 | Detroit | Michigan | — | — |
| 30 | Golden Valley | Minnesota | — | — |
| 71 | Hattiesburg | Mississippi | — | — |
| 31 | Chesterfield | Missouri | — | — |
| 105 | Columbia | Missouri | — | — |
| 66 | St Louis | Missouri | — | — |
| 174 | Omaha | Nebraska | — | — |
| 17 | Lebanon | New Hampshire | — | — |
| 43 | Edison | New Jersey | — | — |
| 67 | Voorhees Township | New Jersey | — | — |
| 36 | Albany | New York | — | — |
| 83 | Buffalo | New York | — | — |
| 69 | Cedarhurst | New York | — | — |
| 154 | Mineola | New York | — | — |
| 122 | New York | New York | — | — |
| 27 | New York | New York | — | — |
| 175 | Schenectady | New York | — | — |
| 3 | Asheville | North Carolina | — | — |
| 63 | Durham | North Carolina | — | — |
| 152 | Rocky Mount | North Carolina | — | — |
| 117 | Wilmington | North Carolina | — | — |
| 47 | Winston-Salem | North Carolina | — | — |
| 15 | Cleveland | Ohio | — | — |
| 61 | Columbus | Ohio | — | — |
| 2 | Toledo | Ohio | — | — |
| 147 | Oklahoma City | Oklahoma | — | — |
| 8 | Medford | Oregon | — | — |
| 157 | Portland | Oregon | — | — |
| 100 | Greensburg | Pennsylvania | — | — |
| 32 | Philadelphia | Pennsylvania | — | — |
| 26 | Tarentum | Pennsylvania | — | — |
| 24 | Beaufort | South Carolina | — | — |
| 114 | Chattanooga | Tennessee | — | — |
| 1 | Nashville | Tennessee | — | — |
| 138 | Austin | Texas | — | — |
| 111 | Dallas | Texas | — | — |
| 22 | Dallas | Texas | — | — |
| 46 | El Paso | Texas | — | — |
| 51 | Houston | Texas | — | — |
| 53 | Houston | Texas | — | — |
| 98 | San Antonio | Texas | — | — |
| 82 | Temple | Texas | — | — |
| 136 | Layton | Utah | — | — |
| 161 | Alexandria | Virginia | — | — |
| 16 | Charlottesville | Virginia | — | — |
| 106 | Richmond | Virginia | — | — |
| 125 | Winchester | Virginia | — | — |
| 74 | Renton | Washington | — | — |
| 80 | Madison | Wisconsin | — | — |
| 28 | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00520741, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 19, 2018 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00520741 live on ClinicalTrials.gov.